Enzymatica AB (publ) (ENZY.ST)
SEK 1.68
(-1.18%)
SEK 1.68
(-1.18%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 24.88 Million SEK | 17.82% |
| 2022 | 21.12 Million SEK | 1779.0% |
| 2021 | 1.12 Million SEK | -45.3% |
| 2020 | 2.05 Million SEK | -39.65% |
| 2019 | 3.4 Million SEK | 12.27% |
| 2018 | 3.03 Million SEK | -31.58% |
| 2017 | 4.43 Million SEK | -24.0% |
| 2016 | 5.83 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 125 Thousand SEK | 0.0% |
| 2009 | 1.68 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 25.56 Million SEK | 0.98% |
| 2024 Q1 | 25.31 Million SEK | 70.43% |
| 2023 Q2 | 21.95 Million SEK | 2.14% |
| 2023 Q1 | 21.49 Million SEK | 1.78% |
| 2023 FY | 24.88 Million SEK | 17.82% |
| 2023 Q4 | 24.88 Million SEK | 2.03% |
| 2023 Q3 | 24.38 Million SEK | 11.09% |
| 2022 Q4 | 21.12 Million SEK | 1.18% |
| 2022 Q1 | 834 Thousand SEK | -25.8% |
| 2022 FY | 21.12 Million SEK | 1779.0% |
| 2022 Q3 | 20.87 Million SEK | 160.27% |
| 2022 Q2 | 8.02 Million SEK | 861.63% |
| 2021 FY | 1.12 Million SEK | -45.3% |
| 2021 Q4 | 1.12 Million SEK | -21.67% |
| 2021 Q2 | 1.56 Million SEK | -9.72% |
| 2021 Q1 | 1.73 Million SEK | -15.43% |
| 2021 Q3 | 1.43 Million SEK | -8.54% |
| 2020 Q2 | 2.56 Million SEK | -19.09% |
| 2020 Q3 | 1.94 Million SEK | -24.25% |
| 2020 Q4 | 2.05 Million SEK | 5.6% |
| 2020 FY | 2.05 Million SEK | -39.65% |
| 2020 Q1 | 3.17 Million SEK | -6.75% |
| 2019 FY | 3.4 Million SEK | 12.27% |
| 2019 Q1 | 3.78 Million SEK | 24.63% |
| 2019 Q2 | 3.13 Million SEK | -16.98% |
| 2019 Q3 | 2.64 Million SEK | -15.68% |
| 2019 Q4 | 3.4 Million SEK | 28.68% |
| 2018 Q1 | 5.29 Million SEK | 19.47% |
| 2018 FY | 3.03 Million SEK | -31.58% |
| 2018 Q3 | 4.31 Million SEK | -10.83% |
| 2018 Q2 | 4.84 Million SEK | -8.61% |
| 2018 Q4 | 3.03 Million SEK | -29.73% |
| 2017 Q3 | 6.04 Million SEK | -8.1% |
| 2017 Q1 | 6.95 Million SEK | 19.18% |
| 2017 Q4 | 4.43 Million SEK | -26.7% |
| 2017 FY | 4.43 Million SEK | -24.0% |
| 2017 Q2 | 6.58 Million SEK | -5.34% |
| 2016 Q4 | 5.83 Million SEK | 0.0% |
| 2016 FY | 5.83 Million SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q2 | - SEK | -100.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | 20.83 Thousand SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | -100.0% |
| 2011 FY | 125 Thousand SEK | 0.0% |
| 2011 Q3 | 374.99 Thousand SEK | -18.18% |
| 2011 Q2 | 458.33 Thousand SEK | 0.0% |
| 2009 FY | 1.68 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | 5.585% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -8112.541% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | -617.739% |
| Nanexa AB (publ) | 2.08 Million SEK | -1092.333% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | 94.45% |
| Probi AB (publ) | 38.21 Million SEK | 34.879% |
| Swedencare AB (publ) | 1.44 Billion SEK | 98.273% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 99.781% |
| Toleranzia AB | 850 Thousand SEK | -2827.529% |
| Vivesto AB | 5.18 Million SEK | -380.293% |